New insider activity at Danaher ( (DHR) ) has taken place on May 4, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Director Alan Spoon has recently sold 1,358 shares of Danaher stock in a transaction valued at $237,201, signaling a notable insider move that may draw attention from investors monitoring executive trading activity.
Recent Updates on DHR stock
Danaher’s shares moved as investors digested a Q1 report showing modest core revenue growth held back by a weak respiratory-testing season and China diagnostics pressure, but offset by strong margins, cash flow and a slight EPS guidance raise. Analysts’ price target revisions largely reflected this mix of solid profitability and bioprocessing momentum versus ongoing policy headwinds in China and lumpy equipment timing, alongside evaluation of the planned Masimo acquisition’s synergies and integration risks.
Spark’s Take on DHR Stock
According to Spark, TipRanks’ AI Analyst, DHR is a Neutral.
DHR scores best on financial quality and the latest earnings call (strong cash generation, solid margins, raised EPS outlook), but the overall score is pulled down by clearly weak technicals (below key moving averages with negative MACD) and a relatively expensive valuation (P/E ~31 with a low yield).
To see Spark’s full report on DHR stock, click here.
More about Danaher
YTD Price Performance: -23.32%
Average Trading Volume: 4,373,710
Technical Sentiment Signal: Sell
Current Market Cap: $124B